|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2004; 43:1929-1939, doi:10.1016/j.jacc.2004.01.035 © 2004 by the American College of Cardiology Foundation |
* Division of Cardiology, Cedars-Sinai Medical Center, and the School of Medicine, University of California, Los Angeles, California, USA
Manuscript received October 1, 2003; revised manuscript received January 2, 2004, accepted January 12, 2004.
* Reprint requests and correspondence: Dr. George A. Diamond, 2408 Wild Oak Drive, Los Angeles, California 90068, USA.
gadiamond{at}pol.net
Large, randomized clinical trials ("megatrials") are key drivers of modern cardiovascular practice, since they are cited frequently as the authoritative foundation for evidence-based management policies. Nevertheless, fundamental limitations in the conventional approach to statistical hypothesis testing undermine the scientific basis of the conclusions drawn from these trials. This review describes the conventional approach to statistical inference, highlights its limitations, and proposes an alternative approach based on Bayes’ theorem. Despite its inherent subjectivity, the Bayesian approach possesses a number of practical advantages over the conventional approach: 1) it allows the explicit integration of previous knowledge with new empirical data; 2) it avoids the inevitable misinterpretations of p values derived from megatrial populations; and 3) it replaces the misleading p value with a summary statistic having a natural, clinically relevant interpretation—the probability that the study hypothesis is true given the observations. This posterior probability thereby quantifies the likelihood of various magnitudes of therapeutic benefit rather than the single null magnitude to which the p value refers, and it lends itself to graphical sensitivity analyses with respect to its underlying assumptions. Accordingly, the Bayesian approach should be employed more widely in the design, analysis, and interpretation of clinical megatrials.
| ||||||||||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  B. Ameer Novel Trial Design: A Report From the 19th Frontiers Symposium of ACCP J. Clin. Pharmacol., July 1, 2008; 48(7): 793 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K J Adhikari and D. C Scales Corticosteroids for acute respiratory distress syndrome BMJ, May 3, 2008; 336(7651): 969 - 970. [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Diamond and S. Kaul COURAGE Under Fire: On the Management of Stable Coronary Disease J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1604 - 1609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kaul, P. K. Shah, and G. A. Diamond As Time Goes By: Current Status and Future Directions in the Controversy Over Stenting J. Am. Coll. Cardiol., July 10, 2007; 50(2): 128 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Eshaghian, S. Kaul, S. Amin, P. K. Shah, and G. A. Diamond Role of Clopidogrel in Managing Atherothrombotic Cardiovascular Disease Ann Intern Med, March 20, 2007; 146(6): 434 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-J. Neumann, A. Kastrati, and G. Schwarzer New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective Eur. Heart J. Suppl., February 1, 2007; 9(suppl_A): A4 - A10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kaul, A. A. Zadeh, and P. K. Shah Homocysteine Hypothesis for Atherothrombotic Cardiovascular Disease: Not Validated J. Am. Coll. Cardiol., September 5, 2006; 48(5): 914 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kaul and G. A. Diamond Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials Ann Intern Med, July 4, 2006; 145(1): 62 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Holzer, M. Mullner, F. Sterz, O. Robak, A. Kliegel, H. Losert, G. Sodeck, T. Uray, A. Zeiner, and A. N. Laggner Efficacy and Safety of Endovascular Cooling After Cardiac Arrest: Cohort Study and Bayesian Approach Stroke, July 1, 2006; 37(7): 1792 - 1797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]
|
|
|
|
|
|
S. Kaul, G. A. Diamond, and W. S. Weintraub Trials and Tribulations of Non-Inferiority: The Ximelagatran Experience J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1986 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Robinson, B. Smith, N. Maheshwari, and H. Schrott Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?: A Meta-Regression Analysis J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1855 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Howard, C. S. Coffey, and G. R. Cutter Is Bayesian Analysis Ready for Use in Phase III Randomized Clinical Trials?: Beware the Sound of the Sirens Stroke, July 1, 2005; 36(7): 1622 - 1623. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Buccelletti Reviparin in Acute Myocardial Infarction JAMA, June 1, 2005; 293(21): 2595 - 2595. [Full Text] [PDF]
|
|
|
|
|
|
American College of Cardiology and the American He, J. A. Spertus, K. A. Eagle, H. M. Krumholz, K. R. Mitchell, and S.-L. T. Normand American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1147 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Spertus, K. A. Eagle, H. M. Krumholz, K. R. Mitchell, S.-L. T. Normand, and for the American College of Cardiology and the Ame American College of Cardiology and American Heart Association Methodology for the Selection and Creation of Performance Measures for Quantifying the Quality of Cardiovascular Care Circulation, April 5, 2005; 111(13): 1703 - 1712. [Abstract] [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
